Medpace Holdings, Inc. $MEDP Shares Sold by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC cut its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 31.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 62,514 shares of the company’s stock after selling 28,895 shares during the quarter. Medpace accounts for approximately 1.9% of Rice Hall James & Associates LLC’s holdings, making the stock its 9th biggest position. Rice Hall James & Associates LLC’s holdings in Medpace were worth $35,111,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Optiver Holding B.V. acquired a new stake in Medpace in the third quarter valued at $27,000. Geneos Wealth Management Inc. lifted its holdings in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. acquired a new stake in Medpace in the fourth quarter valued at $30,000. Elyxium Wealth LLC acquired a new stake in Medpace in the fourth quarter valued at $30,000. Finally, Quarry LP acquired a new stake in Medpace in the third quarter valued at $35,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insider Buying and Selling at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel owned 20,343 shares in the company, valued at $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 20.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have commented on MEDP. Royal Bank Of Canada reduced their target price on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a report on Friday, April 24th. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and reduced their target price for the company from $462.00 to $419.00 in a report on Wednesday, February 18th. Barclays reduced their target price on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a report on Friday, April 24th. Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Robert W. Baird reduced their target price on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $467.08.

Medpace Stock Up 0.0%

Shares of MEDP stock opened at $467.50 on Tuesday. Medpace Holdings, Inc. has a fifty-two week low of $294.07 and a fifty-two week high of $628.92. The stock has a market cap of $13.35 billion, a P/E ratio of 29.38, a P/E/G ratio of 2.37 and a beta of 1.18. The business has a fifty day simple moving average of $455.81 and a 200-day simple moving average of $502.82.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter last year, the business posted $3.67 earnings per share. The business’s revenue for the quarter was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.